Tag Archives: Celgene Corporation

Celgene Advances ABRAXANE® (nab-paclitaxel) Development in Difficult-to-Treat Cancers

Phase III randomized clinical study in metastatic pancreatic cancer completed enrollment sNDA submitted to U.S. FDA in non-small cell lung cancer, PDUFA date Oct. 12, 2012 CALGB 40502 advances understanding of optimal dosing and scheduling of nab-paclitaxel in metastatic breast cancer BOUDRY, Switzerland–(BUSINESS WIRE)–Jun. 6, 2012– Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: […]

Continue Reading

Celgene Completes Acquisition of Avila Therapeutics

SUMMIT, N.J.–(BUSINESS WIRE)–Mar. 8, 2012– Celgene Corporation (NASDAQ: CELG) today announced it has completed its acquisition of Avila Therapeutics. Celgene acquired Avila Therapeutics for $350 million in cash, plus up to $575 million contingent upon certain milestones related to AVL-292 and candidates from Avila’s discovery program. The transaction provides Celgene with a highly-selective Bruton’s tyrosine […]

Continue Reading

Celgene Corporation to Present at Two Upcoming Investor Conferences

SUMMIT, N.J.–(BUSINESS WIRE)–Feb. 27, 2012– Celgene Corporation (NASDAQ: CELG) announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the Company’s Web site at http://www.celgene.com. Celgene management will provide an overview of the Company. •Tuesday, March 6, 2012 Celgene will present at the […]

Continue Reading

Celgene to Acquire Avila Therapeutics

Oral Btk inhibitor AVL-292 offers promising potential for treatment of B-cell diseases Avilomics™ Platform enhances drug discovery capabilities SUMMIT, N.J. and BEDFORD, Mass.–(BUSINESS WIRE)–Jan. 26, 2012– Celgene Corporation (NASDAQ: CELG) and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, today announced a definitive merger agreement […]

Continue Reading

CELGENE CORPORATION ELECTS DR. RICHARD W. BARKER TO ITS BOARD OF DIRECTORS

Celgene Corporation (NASDAQ: CELG) today announced the election of Richard W. Barker, D.Phil., to its Board of Directors. Dr. Barker is a global thought leader in healthcare systems and government policy. He served as Director General of the Association of the British Pharmaceutical Industry (ABPI), and as a board member for the European and International […]

Continue Reading

Celgene Corporation Announces the Appointment of Richard Bagger as Senior Vice President, Corporate Affairs and Strategic Market Access

SUMMIT, N.J.–(BUSINESS WIRE)–Dec. 22, 2011– Celgene Corporation (NASDAQ: CELG) today announced the appointment of Richard Bagger as Senior Vice President, Corporate Affairs and Strategic Market Access, effective January 30th. Mr. Bagger will be responsible for all government and public affairs, strategic market access, communications and patient advocacy initiatives and will report to Robert J. Hugin, […]

Continue Reading

BioNJ Presents Fifth Annual Dr. Sol J. Barer Award for Vision, Innovation, and Leadership to Paul G. Thomas of Roka Bioscience

TRENTON, N.J.–(BUSINESS WIRE)–BioNJ, New Jersey’s trade association for the biotechnology community, announced today that the fifth annual Dr. Sol J. Barer Award for Vision, Innovation, and Leadership has been awarded to Paul G. Thomas, Founder and CEO of Roka Bioscience. Named for Sol J. Barer, Ph.D., a Senior Advisor and former Chairman and CEO of […]

Continue Reading

Final Data from Phase II Multi-Center Study Evaluating Combination of VIDAZA(R) and REVLIMID(R) in Higher-Risk MDS Patients Presented at ASH

Patients achieving complete response had a median overall survival of 27 months BOUDRY, Switzerland, Dec 12, 2011 (BUSINESS WIRE) –Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients […]

Continue Reading

Dosing Study Evaluates REVLIMID® in Previously Treated Patients with Chronic Lymphocytic Leukemia

Study Reported Overall Response Rate of 38%, and REVLIMID® (Lenalidomide) Was Well Tolerated BOUDRY, Switzerland–(BUSINESS WIRE)–Dec. 11, 2011– Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced interim results of CLL-009, a study evaluating three starting doses of REVLIMID® (lenalidomide), followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia […]

Continue Reading

REVLIMID(R) Granted Swissmedic Approval for Treatment of Rare Blood Cancer

REVLIMID(R) Granted Swissmedic Approval for Treatment of Rare Blood Cancer BOUDRY, Switzerland–(BUSINESS WIRE)–Nov. 21, 2011– Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG) today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes […]

Continue Reading
Follow

Get every new post delivered to your Inbox.

Join 85 other followers